Effects of testosterone undecanoate as add-on therapy in obese hypogonadal men that are late responders to tirzepatide: a pilot study - PubMed

3 days ago

Testosterone undecanoate (TRT) was studied as an add-on therapy to tirzepatide in obese hypogonadal men who were late responders to tirzepatide.
The study involved 10 obese men with functional secondary hypogonadism and less than 5% total body weight loss after ≥3 months of tirzepatide treatment.
Participants were divided into two groups: Group A (tirzepatide monotherapy) and Group B (tirzepatide plus testosterone undecanoate).
After 6 months, Group B showed significantly greater weight and fat mass reduction compared to Group A.
Group B also achieved significant lean body mass (LBM) recovery, while Group A experienced progressive LBM loss.
Group B demonstrated restored testosterone levels, improved insulin sensitivity, and better sexual health (IIEF-5 scores).
Physical activity levels nearly doubled in Group B, suggesting increased exercise motivation due to hormonal restoration.
The study concludes that adding TRT to tirzepatide in late responders may optimize weight loss, prevent muscle depletion, and improve metabolic and sexual health.

Hasty Briefsbeta